Glutathione

Glutathione (GSH) is an endogenous tripeptide of glutamate, cysteine, and glycine — the most abundant intracellular antioxidant in the body and not a peptide therapeutic in the conventional sense. It scavenges free radicals and reactive oxygen species, serves as the substrate for Phase II conjugation, recycles vitamins C and E, and supports lymphocyte function.

Synthesis is primarily hepatic. GSH cycles between the active reduced form and the oxidised dimer GSSG; glutathione reductase, using NADPH as electron donor, regenerates GSH. A healthy cell maintains roughly 90% GSH to 10% GSSG, and a shift toward GSSG is a marker of oxidative stress. The cysteine thiol group provides the electron-donating capacity, makes cysteine the rate-limiting precursor, and is also why reconstituted glutathione oxidises quickly in aqueous solution.

Depletion is the therapeutic rationale. Sekhar et al. (2011) found red blood cell glutathione 46.2% lower in adults aged 60 to 75 than in adults aged 30 to 40, attributed to reduced precursor availability rather than enzymatic failure. Chronic stress, illness, environmental toxin exposure, alcohol, acetaminophen, and poor nutrition accelerate depletion, as do cancer, HIV/AIDS, Type 2 diabetes, hepatitis, and Parkinson's disease. Depletion is linked to neurodegenerative, hepatic, cardiovascular, and immune dysfunction and accelerated ageing.

Route matters. Conventional oral glutathione has poor bioavailability because digestive enzymes cleave the tripeptide. Injection delivers reduced GSH directly to circulation; liposomal oral formulations protect the molecule through the gut and raise blood levels in human trials; oral NAC supplies cysteine and reliably raises endogenous synthesis when synthetic capacity is intact.

Glutathione is not FDA-approved for any indication and is available through compounding pharmacies, as a research compound, and as oral supplements. In 2019 the FDA raised concerns about compounded injectables made from dietary supplement-grade material with excessive bacterial endotoxin. Injectable protocols run subcutaneously or intramuscularly.

Direct antioxidant defence. GSH donates electrons to free radicals and reactive oxygen species generated by mitochondrial respiration, terminating the chain reaction of lipid, protein, and DNA oxidation. The resulting GSSG is reduced back to GSH by glutathione reductase with NADPH as electron donor. The cysteine thiol is the active moiety.

Phase II detoxification. Glutathione S-transferases conjugate GSH to xenobiotics, heavy metals (arsenic, cadmium, mercury), drug metabolites, and environmental pollutants, rendering them water-soluble for biliary and urinary excretion. This pathway handles acetaminophen's toxic intermediate NAPQI; when NAPQI exceeds available GSH, hepatic necrosis follows, which is the basis for NAC as standard treatment in acetaminophen overdose.

Antioxidant recycling. GSH regenerates oxidised ascorbate and tocopherol to their active forms, making it the hub of the antioxidant network. GSH depletion accelerates consumption of vitamins C and E.

Immune modulation. Lymphocyte function is sensitive to modest shifts in intracellular GSH. NK cell cytotoxicity, T-cell proliferation, and macrophage activity all depend on adequate GSH. In deficiency states such as HIV infection, NAC supplementation almost completely restored NK cell activity. In healthy individuals with adequate GSH, supplementation has not been shown to produce further immune enhancement — the effect is deficiency-dependent.

Mitochondrial protection. Mitochondria are both the principal ROS generators and the most ROS-vulnerable compartment, since mitochondrial DNA lacks nuclear repair mechanisms. Oxidative damage lowers ATP output and raises ROS production in a self-reinforcing cycle that GSH interrupts at source.

GSH is also the substrate for glutathione peroxidase, which is why its depletion has broad downstream consequences and why compounds such as Thymosin Alpha-1 are described as supporting glutathione pathways rather than replacing them.

Redox and detoxification. Reduction of oxidative stress and conjugation and clearance of xenobiotics and heavy metals. Kalamkar et al. (2022): 500 mg oral daily for six months in 250 diabetic patients significantly raised blood glutathione (Cohen's d = 1.01) and reduced 8-OHdG (Cohen's d = -1.07).

Hepatic. Toxin clearance and hepatoprotection; a non-alcoholic fatty liver disease study reported improved liver enzymes after four months of consistent dosing.

Immune and inflammatory. Sinha et al. (2018): liposomal glutathione raised NK cell cytotoxicity by up to 400% and lymphocyte proliferation by up to 60% within two weeks in healthy adults, with the caveat that the effect is most significant in deficiency states. Reduced inflammation and oxidative contribution to chronic conditions including autoimmune disease.

Dermatological. Skin lightening via tyrosinase inhibition and a shift from eumelanin to pheomelanin; five RCTs at 250 to 500 mg oral daily showed significant melanin index reductions versus placebo. Weschawalit et al. (2017) also reported improved elasticity, wrinkles, and smoothness. Reduced photoageing.

Neurological. Substantia nigra glutathione is 30 to 50% lower in post-mortem Parkinson's tissue. A 2020 meta-analysis of seven RCTs (450 participants) found a pooled UPDRS III effect size of -0.48 (P=0.02) with no cognitive or mood benefit. Reduced neuronal damage post-stroke has been reported.

Mitochondrial. Protection from oxidative damage supporting cellular energy production; depletion is associated with fatigue.

Ophthalmic. Long-term retinal, lens, and corneal health; Müller cell support; reduced ocular oxidative stress; delayed age-related loss of visual acuity and cataract incidence.

Performance and other. Pre-exercise administration improves skeletal muscle lipid metabolism and acidification handling, reducing fatigue; improved cartilage health; combats male infertility; mitigates radiation and chemotherapy toxicity; may assist weight loss. With L-citrulline, maximised nitric oxide production and vasodilation.

Published timepoints. Richie et al. (2015): at 1000 mg oral daily, blood glutathione rose within the first month with maximum 30 to 35% increases in erythrocytes and plasma at six months; NK cytotoxicity more than doubled at three months. Sinha et al. (2018): liposomal glutathione raised levels within one week, peaking at two weeks (40% whole blood, 25% erythrocytes, 100% PBMCs), with NK cytotoxicity up to 400%. Arjinpathana and Asawanonda (2012): melanin index fell consistently over four weeks at 500 mg daily, with significance versus placebo at two of six sites. Kalamkar et al. (2022): significant glutathione elevation within three months at 500 mg daily with concurrent decline in oxidative damage markers. No published timepoints exist for subcutaneous injection.

Reported timelines. Anecdotal, not published data.

Weeks 1 to 2: some report improved mental clarity and energy within days, particularly with IV or injectable routes. Others experience transient worsening — headache, fatigue, irritability, flu-like symptoms — described as detox reactions, more common with high toxic burden (mould, heavy metals, chronic infection) and higher starting doses; these typically resolve within 1 to 2 weeks or with dose reduction. Injection site reactions are most frequent early.

Weeks 2 to 4: energy improvements consolidate; detox symptoms resolve; no visible skin change yet.

Weeks 4 to 8: skin brightening becomes apparent where it occurs, dose-dependent and highly individual; wellbeing stabilises; immune improvements are reported.

A subset report no benefit from IV or injection, and some report instant irritability, mood changes, dizziness, or headaches. Injection site pain and large injection volumes are the most common complaints.

After cessation: levels return gradually to baseline with no withdrawal or rebound; benefits and skin changes reverse over weeks to months. Dietary sulphur and cruciferous intake and oral NAC support endogenous synthesis between cycles.

Evidence base. Published dosing is oral (250 to 1000 mg daily for 4 weeks to 6 months), liposomal (500 to 1000 mg daily for 4 weeks, no dose difference), IV (600 mg twice daily for 30 days, Sechi et al.; 1400 mg three times weekly for 4 weeks, Hauser et al.; 1200 mg twice weekly for 6 weeks with a 32% adverse event rate), and intranasal (300 to 600 mg daily for 3 months, Mischley et al., 2015). No dose-finding data exist for subcutaneous use; the injectable protocols are clinical practice patterns.

Subcutaneous. Conservative 100 mg three times weekly, 8 to 12 weeks; standard 200 mg three times weekly, 8 to 12 weeks; intensive 200 mg daily or 5×/week, 4 to 8 weeks. Weekly totals 300 to 1000 mg.

Intramuscular. Starting 200 mg weekly for 4 weeks; maintenance 400 to 600 mg weekly ongoing; maximum 800 to 1000 mg weekly as needed, escalating every 4 weeks on tolerance and response. Practitioners favour 100 to 200 mg weekly starts, since detox reactions scale with toxic burden and starting dose.

Cycling. 8 to 12 weeks on, 4 weeks off, with continuous oral liposomal glutathione or NAC; periodic zinc monitoring on long-term use given the bidirectional zinc–glutathione relationship. The alternative protocol below uses a 1,500 mg vial in 7 mL (214.3 mg/mL, 46 units = 100 mg) at 100 mg daily, six days weekly, on a 4-week maximum cycle; that concentration exceeds the 20 to 50 mg/mL solubility range cited here and should be regarded as superseded.

Reconstitution. Published solubility of reduced glutathione is approximately 20 mg/mL (Cayman Chemical, Santa Cruz Biotechnology) to 50 mg/mL (G Biosciences). A 600 mg vial takes 6 mL (100 mg/mL) or 12 mL (50 mg/mL); 2 to 3 mL yields 200 to 300 mg/mL and precipitation. Run diluent down the vial wall, swirl, do not shake; if flakes persist after 30 minutes add water to 12 mL total. At 100 mg/mL: 100 mg = 1.0 mL (100 units), 200 mg = 2.0 mL, 300 mg = 3.0 mL, 600 mg = 6.0 mL. At 50 mg/mL: 100 mg = 2.0 mL, 200 mg = 4.0 mL, 300 mg = 6.0 mL. Larger volumes may require two sites or intramuscular delivery.

Stability. The cysteine thiol oxidises readily to GSSG in aqueous solution. US Patent 6835811 showed 10 to 15% monthly loss at room temperature versus 0 to 5% below 15°C; Tad-600 prescribing information limits reconstituted stability to 8 hours at room temperature and 48 hours refrigerated in sterile water. Bacteriostatic water does not prevent thiol oxidation, so the 28-day convention does not apply: refrigerate at 2 to 8°C, protect from light, do not freeze, use within 14 days. Inspect before each injection; clear and colourless to very slightly pale yellow is acceptable; cloudiness, yellow-brown discolouration, particulates, or sulphur odour indicate degradation.

The intramuscular maximum of 800 to 1,000 mg weekly (as needed) exceeds a single 600 mg vial and is therefore given in prose only; it requires two vials per injection. Weekly totals on the subcutaneous schedules range from 300 to 1,000 mg.

The evidence base establishes that supplementation raises systemic GSH and lowers oxidative-damage biomarkers; clinical endpoints are weaker, and no published dose-finding data exist for subcutaneous protocols.

Richie et al. (2015): randomised, double-blind, placebo-controlled; 54 healthy adults at 250 mg/day, 1000 mg/day, or placebo for six months. High dose produced 30 to 35% increases in erythrocyte, plasma, and lymphocyte GSH and a 260% increase in buccal cells; NK cytotoxicity more than doubled at three months. Limitation: modest n in a healthy population.

Sinha et al. (2018): 12 healthy adults, 500 or 1000 mg liposomal daily for four weeks. GSH rose 40% in whole blood, 25% in erythrocytes, 28% in plasma, 100% in PBMCs by two weeks; plasma 8-isoprostane fell 35%, GSSG:GSH ratio fell 20%; NK cytotoxicity up to 400%, lymphocyte proliferation up to 60%. No dose separation; n=12.

Kalamkar et al. (2022): 354 participants (250 diabetic, 104 controls); 125 diabetics received 500 mg oral daily for six months with standard therapy. Blood GSH rose (Cohen's d = 1.01), 8-OHdG fell (d = -1.07); HbA1c stabilisation most marked over age 55. 44 lost to follow-up.

Parkinson's: Sechi et al. (1996), open-label, 9 early untreated patients, 600 mg IV twice daily for 30 days, 42% decline in disability scores persisting 2 to 4 months; uncontrolled. Hauser et al. (2009), RCT, 21 subjects, 1400 mg IV three times weekly for four weeks, 2.8-unit UPDRS motor advantage, P=0.32, no persistence at eight weeks; underpowered. 2020 meta-analysis of seven RCTs (450 participants): pooled UPDRS III effect -0.48 (P=0.02), no cognitive, mood, or ADL effect, raised serum glutathione peroxidase, no excess adverse events. Substantia nigra GSH is 30 to 50% reduced post mortem in PD.

Dermatological: Arjinpathana and Asawanonda (2012), 60 participants, 500 mg oral daily divided for four weeks, melanin index reduced at all six sites, significant at two. Weschawalit et al. (2017), 250 mg daily for 12 weeks, reduced melanin index with improved elasticity, wrinkles, and smoothness; both GSH and GSSG were effective.

Ageing: Sekhar et al. (2011), 8 elderly versus 8 young; 46.2% lower erythrocyte GSH at baseline; 14 days of NAC plus glycine produced 94.6% higher GSH and 78.8% higher synthesis rates, normalising oxidative markers. Deficit is precursor-limited, not enzyme-limited.

Safety: Marrades et al. (1997), 8 mild asthmatics, nebulised GSH gave FEV1 -19% and airway resistance +61% via sulfite formation. Alzahrani et al. (2025) narrative review: 32% adverse event rate at 1200 mg IV twice weekly including hepatic dysfunction and one anaphylaxis. Mischley et al. (2015): intranasal 300 to 600 mg daily for 3 months tolerable, efficacy not demonstrated.

Immune effects are most pronounced in deficiency states; in replete individuals further enhancement has not been shown.